Epic Sciences Appoints Michael Giske as Chief Information Officer

Print 21 October 2014

SAN DIEGO – October 20, 2014 – Epic Sciences announced the appointment of Michael Giske as chief information officer. Mr. Giske has more than 25 years of defining, designing and implementing secure, global, large-scale technology solutions to deliver innovative and impactful products. At Epic, he will lead the IT strategy and execution for the company’s diagnostics platform, which includes Epic’s circulating tumor cell (CTC) technology. From the accurate and rapid enumeration and characterization of CTCs, Epic provides essential information for superior therapy selection and early drug resistance detection to improve the treatment of cancer.

“Michael is a visionary technology leader with expertise in developing and implementing cloud-based architecture solutions for data-driven businesses and providing efficient and secure interactions with partners around the world,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. “At Epic, Michael will architect and deliver a secure, global information technology blueprint for the Epic platform to supply critical and actionable insights about the disease status and therapeutic response of a patient’s cancer across each clinical decision point.”

“Throughout my career, I have been drawn to unique opportunities to find new ways to solve critical problems with technology,” said Mr. Giske. “Epic not only has an exceptionally talented team, but also an unrivalled rare cell detection, quantification and characterization platform that can transform how cancer is treated and managed. These actionable data insights will allow Epic to expand into broad reaching informatics solutions and related services.”

Mr. Giske has more than 25 years of experience in developing innovative technology solutions for the health and life sciences industry among other verticals.  Before joining Epic, Mr. Giske was director of IT Strategy and Architecture at Oracle Corporation, where he securely enabled service-oriented and cloud-based solutions. Prior to Oracle, he was CEO and Managing Partner at KPMGS, a provider of information technology solutions and services and served for more than 16 years as chief architect for large-scale global IT initiatives for research, corporate and clinical solutions for large life science organizations. Mr. Giske also has developed or led a number of firsts in the industry, including the first energy trading system and internet-based meter and customer control system for Sempra Energy, the first online software ordering system for Apple Inc., and the first global large-scale call center and knowledge system for Disney Interactive. Mr. Giske earned his bachelor’s degree in computer science from San Diego State University.

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point.  Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

 

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news